ArticleAdvanced healthcare materials2025
3D Bioprinted Renal Constructs Using Kidney-Specific ECM Bioink System on Kidney Regeneration.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- 3D bioprinting of tissues and organs for systemic diseases and localized injuries.Military Medical Research · 2026Review
- Revolutionizing Renal Replacement: Current Advancements in Development and Transplantation of Bioengineered Kidneys.International journal of molecular sciences · 2026Review
- Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches.Kidney international · 2026Review
- 3D Bioprinted Renal Constructs Using Kidney-Specific ECM Bioink System on Kidney Regeneration.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The final stage of chronic kidney disease (CKD) remains an irreversible condition, with dialysis and transplantation as the only treatment options. Recently, 3D bioprinting has emerged as a promising strategy for bioengineering renal constructs capable of restoring damaged kidney. A critical challenge in this approach is the development of a kidney-specific bioink that provides an optimal biochemical and biomechanical microenvironment to support renal cell organization, maturation, and functional restoration. In this study, a kidney-derived decellularized extracellular matrix bioink (kdECMMA) to facilitate renal tissue bioprinting is utilized. The kdECMMA bioink exhibits excellent printability, structural integrity, and biological characteristics. Human kidney cells encapsulated within the bioprinted kdECMMA constructs demonstrate high viability and progressive maturation over time. To evaluate its in vivo feasibility, bioprinted renal constructs into the kidneys of nude rats are implanted. After 1 and 2 months, the implanted constructs display newly formed glomerular- and tubular-like structures, with human-specific markers confirming the integration of human cells within these formations. Particularly, renal tissue formation is also observed in cell-free kdECMMA constructs, suggesting the recruitment of host renal progenitor cells into the implantation site. These findings highlight the potential of kdECMMA bioinks in creating a kidney-specific microenvironment conducive to renal regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.